Demographic and comorbidity profile of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a real-life clinical setting: Are 5-alpha-reductase inhibitor consumers different?
- 10 December 2014
- journal article
- research article
- Published by Springer Nature in World Journal of Urology
- Vol. 33 (5) , 685-689
Abstract
We aimed to describe, in a daily clinical practice setting, the demographic and comorbidity profile of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (BPH-LUTS), to compare the characteristics of patients receiving 5-alpha-reductase inhibitors (5-ARIs) with those not receiving them and to investigate predictors of 5-ARI prescription. We performed a retrospective observational study using data retrieved from a general practitioners database. Male patients with diagnosis of BPH-LUTS were included. The following demographic and clinical data were available and extracted: age, comorbidities, BPH-LUTS medical therapy, drugs for comorbidities. A subgroup analysis was performed according to the use of 5-ARIs. Factors associated with 5-ARI prescription were assessed with uni- and multivariate analyses. A total of 7,103 patients were identified. Most patients (71.7 %) were aged ≥65 years. Hypertension was present in 64.9 % of patients; it was the most prevalent comorbidity followed by diabetes mellitus, hypercholesterolemia, coronary artery disease and other dyslipidemias. Overall, 38.22 % of patients were treated with 5-ARIs. Mean age of patients taking 5-ARIs was significantly higher. The prevalence of hypertension and the use of antihypertensive drugs were significantly higher among patients receiving 5-ARIs. Older age was an independent predictor of 5-ARI prescription. In a daily clinical practice setting, patients with BPH-LUTS receiving 5-ARIs are significantly older and have significantly higher prevalence of hypertension if compared with patients with BPH-LUTS not receiving 5-ARIs. Older age is an independent predictor of 5-ARI prescription.Keywords
This publication has 15 references indexed in Scilit:
- Effects of 5-alpha reductase inhibitors on erectile function, sexual desire and ejaculationExpert Opinion on Drug Safety, 2012
- The Impact of Diabetes Type 2 in the Pathogenesis of Benign Prostatic Hyperplasia: A ReviewAdvances in Urology, 2009
- Diabetes and benign prostatic hyperplasia: Emerging clinical connectionsCurrent Urology Reports, 2009
- 5-Alpha Reductase Inhibitors and Erectile Dysfunction: The ConnectionThe Journal of Sexual Medicine, 2008
- Physician perceptions of sexual dysfunction related to benign prostatic hyperplasia (BPH) symptoms and sexual side effects related to BPH medicationsInternational Journal Of Impotence Research, 2007
- The Role of Nitric Oxide in Erectile Dysfunction: Implications for Medical TherapyThe Journal of Clinical Hypertension, 2006
- BPH: epidemiology and comorbidities.2006
- Safety and Tolerability of the Dual 5α-Reductase Inhibitor Dutasteride in the Treatment of Benign Prostatic HyperplasiaEuropean Urology, 2003
- Incidence and Prevalence of Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia in Primary Care—The Triumph ProjectEuropean Urology, 2002
- Worldwide patterns of prevalence and mortality from benign prostatig hyperplasiaUrology, 1995